Gout drug ‘has no benefit’ in ischaemic heart disease
Researchers have ruled out allopurinol for secondary prevention after conducting the largest study to date examining potential cardiovascular benefits
Doctors have been urged to avoid allopurinol for secondary prevention of major cardiac events in over-60s with ischaemic heart disease following results from a landmark trial.
UK researchers report that off-label use of the xanthine oxidase inhibitor in this setting does not reduce the risk of cardiovascular death, MI or stroke compared with usual care.
